Comparative effects of sitagliptin and metformin in patients with type 2 diabetes mellitus: a meta-analysis

References

• Imperatore G, Boyle JP, Thompson TJ, et al. Projections of type 1 and type 2 diabetes burden in the U.S. population aged <20 years through 2050: dynamic modeling of incidence, mortality, and population growth. Diabetes Care 2012;35:2515-20
   PubMed Web of Science ®Google Scholar
• Unwin N, Guariguata L, Whiting D, et al. Complementary approaches to estimation of the global burden of diabetes. Lancet 2012;379:1487-8
   PubMed Web of Science ®Google Scholar
• El-Menyar A, Al Thani H, Hussein A, et al. Diabetic retinopathy: a new predictor in patients on regular hemodialysis. Curr Med Res Opin 2012;28:999-1055
   PubMed Web of Science ®Google Scholar
• Boonman-de Winter LJ, Rutten FH, Cramer MJ, et al. High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia 2012;55:2154-62
   PubMed Web of Science ®Google Scholar
• Braga MF, Casanova A, Teoh H, et al. Poor achievement of guidelines-recommended targets in type 2 diabetes: findings from a contemporary prospective cohort study. Int J Clin Pract 2012;66:457-64
   PubMed Web of Science ®Google Scholar
• Liu SC, Tu YK, Chien MN, et al. Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis. Diabetes Obes Metab 2012;14:810-20
   PubMed Web of Science ®Google Scholar
• Liang J, Leung KK, Lam SY, et al. Combined treatment with a dipeptidyl peptidase-IV inhibitor (sitagliptin) and an angiotensin II type 1 receptor blocker (losartan) promotes islet regeneration via enhanced differentiation of pancreatic progenitor cells. Diabetes Obes Metab 2012;14:842-51
   PubMed Web of Science ®Google Scholar
• Derosa G, Cicero AF, Franzetti IG, et al. A randomized, double-blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetes patients already treated with pioglitazone and metformin: a 3-year study. Diabetes Technol Ther 2013;15:214-22
   PubMed Web of Science ®Google Scholar
• Derosa G, Carbone A, D’Angelo A, et al. A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and β-cell function. Expert Opin Pharmacother 2012;13:2433-42
   PubMed Web of Science ®Google Scholar
• Derosa G, Ragonesi PD, Fogari E, et al. Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation. Fundam Clin Pharmacol 2012;11:12001
   Google Scholar
• Muscelli E, Casolaro A, Gastaldelli A, et al. Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab 2012;97:2818-26
   PubMed Web of Science ®Google Scholar
• Ross SA, Dzida G, Vora J, et al. Impact of weight gain on outcomes in type 2 diabetes. Curr Med Res Opin 2011;27:1431-8
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 2007;28:105-14
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58
   PubMed Web of Science ®Google Scholar
• Russell-Jones D, Cuddihy RM, Hanefeld M, et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care 2012;35:252-8
   PubMed Web of Science ®Google Scholar
• Williams-Herman D, Xu L, Teng R, et al. Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes. Diabetes Obes Metab 2012;14:67-76
   PubMed Web of Science ®Google Scholar
• Aschner P, Katzeff HL, Guo H, et al. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab 2010;12:252-61
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P, Salvadeo SA, et al. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism 2010;59:887-95
   PubMed Web of Science ®Google Scholar
• Goldstein BJ, Feinglos MN, Lunceford JK, et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30:1979-87
   PubMed Web of Science ®Google Scholar
• Dan W, Yuzhi Y, Kun F, et al. Effects of sitagliptin in serum inflammatory factors of patients with type 2 diabetes mellitus. J Practical Diabetol 2012;8:54-5
   Google Scholar
• Wanjun W, Qinli Y, Chuan T, et al. Efficacy initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes mellitus: a clinical study. Guide China Med 2012;18:222-4
   Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-19
   PubMed Web of Science ®Google Scholar
• Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-95
   PubMed Web of Science ®Google Scholar
• Kishimoto M, Noda M. A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers. Cardiovasc Diabetol 2011;10:115
   PubMed Web of Science ®Google Scholar
• Lund A, Knop FK. Worry vs. knowledge about treatment-associated hypoglycaemia and weight gain in type 2 diabetic patients on metformin and/or sulphonylurea. Curr Med Res Opin 2012;28:731-6
   PubMed Web of Science ®Google Scholar
• Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care 2012;35:731-7
   PubMed Web of Science ®Google Scholar
• National Collaborating Centre for Chronic Conditions (UK). Type 1 Diabetes in Adults: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care. London: Royal College of Physicians (UK), 2004
   Google Scholar
• Ellis SL, Moser EG, Snell-Bergeon JK, et al. Effect of sitagliptin on glucose control in adult patients with type 1 diabetes: a pilot, double-blind, randomized, crossover trial. Diabet Med 2012;28:1176-81
   Web of Science ®Google Scholar
• Paiva M, Riksen NP, Davidson SM, et al. Metformin prevents myocardial reperfusion injury by activating the adenosine receptor. J Cardiovasc Pharmacol 2009;53:373-8
   PubMed Web of Science ®Google Scholar
• Calvert JW, Gundewar S, Jha S, et al. Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling. Diabetes 2008;57:696-705
   PubMed Web of Science ®Google Scholar
• Sauvé M, Ban K, Momen MA, et al. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes 2010;59:1063-73
   PubMed Web of Science ®Google Scholar
• Monami M, Lamanna C, Desideri CM, et al. DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther 2012;29:14-25
   PubMed Web of Science ®Google Scholar
• Derosa G, Carbone A, Franzetti I, et al. Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients. Diabetes Res Clin Pract 2012;98:51-60
   PubMed Web of Science ®Google Scholar
• Vergès B, Bonnard C, Renard E. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system. Diabetes Metab 2011;37:477-88
   PubMed Web of Science ®Google Scholar
• Monami M, Dicembrini I, Marchionni N, et al. Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis. Exp Diabetes Res 2012;2012:672658
   PubMedGoogle Scholar
• Kosinski JR, Hubert J, Carrington PE, et al. The glucagon receptor is involved in mediating the body weight-lowering effects of oxyntomodulin. Obesity (Silver Spring) 2012;20:1566-71
   PubMed Web of Science ®Google Scholar
• Monami M, Dicembrini I, Martelli D, et al. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin 2012;27:57-64
   Web of Science ®Google Scholar
• Schulz KF, Chalmers I, Hayes RJ, et al. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12
   PubMed Web of Science ®Google Scholar
• Chalmers TC, Celano P, Sacks HS, et al. Bias in treatment assignment in controlled clinical trials. N Engl J Med 1983;309:1358-61
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097
   PubMed Web of Science ®Google Scholar
• Williams-Herman D, Johnson J, Teng R, et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab 2010;12:442-51
   PubMed Web of Science ®Google Scholar
• Williams-Herman D, Johnson J, Teng R, et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Curr Med Res Opin 2009;25:569-83
   PubMed Web of Science ®Google Scholar